RT Journal Article
SR Electronic
T1 N Gene Target Failure (NGTF) for detection of Omicron: a way out for the ‘stealth’ too?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.28.22269801
DO 10.1101/2022.01.28.22269801
A1 Harankhedkar, Shivangi
A1 Chatterjee, Gaurav
A1 Rajpal, Sweta
A1 Khan, Afreen
A1 Srivastava, Tuhina
A1 Mirgh, Sumeet
A1 Gokarn, Anant
A1 Punatar, Sachin
A1 Shetty, Nitin
A1 Joshi, Amit
A1 Nair, Sudhir
A1 Murthy, Vedang
A1 Tembhare, Prashant
A1 More, Ashwini
A1 Kamtalwar, Sujeet
A1 Chavan, Preeti
A1 Bhat, Vivek
A1 Patil, Amar
A1 Dhumal, Sachin
A1 Bhat, Prashant
A1 Subramanian, Papagudi
A1 Tripathi, Rachana
A1 Munipally, Shesheer
A1 Gujral, Sumeet
A1 Khattry, Navin
A1 Gupta, Sudeep
A1 Patkar, Nikhil
YR 2022
UL http://medrxiv.org/content/early/2022/02/01/2022.01.28.22269801.abstract
AB S-gene target failure (SGTF) is neither specific nor accurate for identification of Omicron lineage of SARS-CoV-2. We observed N-gene target failure (NGTF) in 402 out of 412 SARS-CoV2 positive cases from December to mid-January 2022 using a commercially available assay. This phenomenon was not observed with more than 15,000 cases tested previously. We sequenced the genome of five samples with NGTF and compared these results with six cases where NGTF was not seen. We confirm that cases with NGTF were the Omicron lineage while cases with preserved N-gene amplification belonged to Delta lineage. We discovered that the ERS31-33 deletion (nucleotide 28362-28370del) overlaps with N gene probe used, explaining NGTF. As the ‘stealth’ Omicron variant also harbors ERS31-33 deletion, this approach will work for the detection of ‘stealth’ Omicron variant as well. We suggest that NGTF can be used as a low cost, rapid screening strategy for detection of Omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper was approved by the Tata Memorial Centre- Institutional Ethics CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors